CryoLife Completes Acquisition of Jotec


December 1, 2017—CryoLife, Inc., a United States-based medical device and tissue processing company focused on cardiac and vascular surgery, announced that it has completed its previously announced acquisition of Jotec GmbH, a German-based, privately held developer of technologically differentiated endovascular stent grafts and cardiac and vascular surgical grafts, focused on aortic repair.

In October, the companies announced the agreement under which CryoLife would acquire Jotec for $225 million, consisting of 75% in cash and up to 25% in CryoLife common stock issued to Jotec’s shareholders. The acquisition creates an international company with more than 1,000 employees dedicated to the field of medical products for cardiovascular surgery.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.